ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / GRFS / financials
MIRM (51) COGT (42) MANE (55) ERAS (33) ⌘ Pro Terminal →

Grifols S.A. (GRFS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$8.51 +5.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.57

Grifols S.A. (GRFS) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $5.57B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GRFS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GRFS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Grifols S.A. (NASDAQ: GRFS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $8.51 (+5.06% 1D, market cap $5.57B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, GRFS ranks #213 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GRFS compare to MIRM and COGT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GRFS carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MIRM (Mirum Pharmaceuticals Inc.) holds a D grade (51/100 RQD, P/E N/A, ROIC -3.9%, cap $5.52B) and COGT (Cogent Biosciences Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $5.38B). Among the 5-stock peer group, GRFS leads on earnings multiple (N/A) while MIRM leads on capital efficiency (-3.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GRFS?
▼

For Grifols S.A. (GRFS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #213 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $8.57 (+0.72%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 3.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510054
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D+ · Rk D+
Cash (12)Whales (11)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-1.8% Base Target
$10 Bull$8 Base$7 Bear
📬 FREE GRFS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRFS)Realized 20D OHLCV Swing Band: ±5%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY GRFS SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (22% of score)

SEC XBRL Trailing 12 Months: 3.9% FCF Margin ($155.9M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
46
Grade D$7.37+3.7% Next Q
Q2 (-2Q)
49
Grade D$7.64+3.7% Next Q
Q3 (-1Q)
51
Grade C-$7.92+7.4% Next Q
Current
54
Grade D+$8.51-0.7% Hist 90D α
Trajectory: D (46) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GRFS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GRFS currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.59) and Max Pain ($8.94) forces dealer call-delta covering toward $10.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GRFS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GRFS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 54%NO 46%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How GRFS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$155.9M (3.9% FCF Margin)
Revenue$4.00BGross Profit $2.08B (52%)Cost of Sales $1.92BOp Profit $1.08B (27%)OpEx (R&D/SG&A) $998.4MNet Profit$865.3M (21.6%)Tax/Other $216.3M
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GRFS)

  • ✓Walkthrough of GRFS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GRFS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.40%⚡ TESTING RESISTANCE
2026-11-03O $8.04H $8.51L $8.04C $8.51VOL 803.4K
RES: $8.55SUP: $7.19SMA50: $7.59SMA200: $7.99
$9.34$8.69$8.05$7.40$6.76RES $8.55SUP $7.19$8.512026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GRFS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GRFS Butterfly Map → + Track GRFS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GRFS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GRFS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GRFS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRFS)

Health Care Rank #213 of 1015 ⚔️ MIRM vs GRFS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GRFS vs. MIRM, COGT, MANE, ERAS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Grifols S.A. (GRFS) ranks #213 by composite RQD confidence (54/100, grade D+) and #149 by equity capitalization ($5.57B). Within this direct 5-issuer industry benchmark cohort, GRFS leads on earnings valuation at N/A trailing P/E, while MIRM leads on capital efficiency and profitability with -3.9% ROIC and — gross margin. MANE currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with GRFS at 54/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GRFS ACTIVE
Grifols S.A.
D+ 54/100 — — — +5.06% $5.57B Benchmark Subject
MIRM
Mirum Pharmaceuticals Inc.
D 51/100 — — -3.9% +0.87% $5.52B /mirm-vs-grfs →
COGT
Cogent Biosciences Inc.
D- 42/100 — — -35.0% -4.16% $5.38B /cogt-vs-grfs →
MANE
Veradermics Incorporated
D+ 55/100 — — -11.9% -7.27% $5.84B /mane-vs-grfs →
ERAS
Erasca Inc.
E 33/100 — — -35.0% -2.09% $5.02B /eras-vs-grfs →

2. GRFS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Grifols S.A. (GRFS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $5.57B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. GRFS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GRFS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Grifols S.A. (NASDAQ: GRFS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $8.51 (+5.06% 1D, market cap $5.57B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, GRFS ranks #213 in composite RQD confidence.

How does GRFS compare to MIRM and COGT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GRFS carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MIRM (Mirum Pharmaceuticals Inc.) holds a D grade (51/100 RQD, P/E N/A, ROIC -3.9%, cap $5.52B) and COGT (Cogent Biosciences Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $5.38B). Among the 5-stock peer group, GRFS leads on earnings multiple (N/A) while MIRM leads on capital efficiency (-3.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GRFS?

For Grifols S.A. (GRFS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #213 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GRFS trading relative to its 50-day, 200-day, and 52-week technical levels?

GRFS last traded at $8.51 (+5.06% on volume of 1,586,680 shares), positioning the stock +12.12% above its 50-day simple moving average ($7.59) and +6.51% above its 200-day simple moving average ($7.99). Across its 52-week range of $6.96 to $9.90, GRFS sits at the 52.7% percentile with a 14-day RSI of 66.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.0% ($8.08 to $8.94).

Direct Sub-Reports: GRFS RQD Cockpit GRFS 12M Forecast GRFS Earnings & Move GRFS Dividends & DRIP GRFS Insiders & 13F GRFS Whale Options GRFS Profit Sankey GRFS News & Why
ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ SEC XBRL & RQD VERIFIED

GRFS — Grifols S.A.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Grifols S.A. (GRFS) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $8.51 (+5.06% 1D, market capitalization $5.57B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Grifols S.A. (GRFS) is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry,. The profile describes the company with a market capitalization of $5.5B. — The sources do not describe products, customers, or revenue model.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 54/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 11/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $6.96 – $9.90 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The Butterfly Supply-Chain Graph lists no upstream or downstream links, no sector correlations, and no proprietary signals. Second-order dependencies cannot be assessed from the provided data.

  • Key Question #1: Can GRFS sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $9.90 52-week high?
  • Key Question #3: How sensitive is GRFS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

GRFS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Grifols S.A. (GRFS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GRFS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GRFS Bull vs. Bear Conversation Board — What's Your Call at $8.51?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GRFS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on GRFS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $9.88 (+22.0%)
📌 Pinned Debate

The plasma-demand catalyst headline and a 7.2% share climb suggest near-term sentiment momentum that could support a recovery narrative

Picked up a starter position in GRFS in my $100K Virtual Cash book at $8.10. The plasma-demand catalyst headline and a 7.2% share climb suggest near-term sentiment momentum that could support a recovery narrative.. Trading inside a $6.96–$9.90 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader 🐂 BULL

Both sides have a point here — GRFS's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $6.64 (-18.0%)
Spot @ $8.10

A 0% ROIC and 0% FCF yield, combined with a 105.0% short-interest increase, point to weak cash generation and rising bearish positionin

Here is the bear case nobody on the bull side wants to address on GRFS: A 0% ROIC and 0% FCF yield, combined with a 105.0% short-interest increase, point to weak cash generation and rising bearish positioning.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE